Companies Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals (AMRX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Amneal Pharmaceuticals, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers33rd pct.Of 12 peer CEOs
CEO pay, last three years
- $7,187,970FY2024
- $8,691,745FY2025
CEO total pay was $8,691,745 in fiscal 2025, up from $7,187,970 in fiscal 2024.
FY2025: salary $800,000 · bonus $0 · stock awards $6,974,995 · option awards $0
Executives and directors
Andrew Boyer · CCOChirag Patel · CEOJason Daly · General CounselAnastasios Konidaris · CFONikita Shah · ExecutiveChintu Patel · DirectorDeb Autor · Independent DirectorEmily Peterson Alva · Former director (through FY2025)Gautam Patel · Independent DirectorJ. Kevin Buchi · Independent DirectorJeff George · Independent DirectorJohn Kiely · Independent DirectorPaul Meister · Chair of the BoardShlomo Yanai · Independent DirectorTed Nark · Independent Director
Frequently asked questions
Who was the highest-paid executive at Amneal Pharmaceuticals, Inc. in fiscal 2025?
As disclosed, Chirag Patel (Co-Chief Executive Officer and President) was the highest-paid executive at Amneal Pharmaceuticals, Inc. in fiscal 2025, with total compensation of $8,691,745.
How does Amneal Pharmaceuticals, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Chirag Patel's total compensation ranked at the 33rd percentile of Amneal Pharmaceuticals, Inc.'s disclosed peer group.
What is Amneal Pharmaceuticals, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Amneal Pharmaceuticals, Inc.'s CEO-to-median employee pay ratio was 679:1.
How did shareholders vote on Amneal Pharmaceuticals, Inc.'s executive compensation?
As disclosed, 99.05% of shareholders supported Amneal Pharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Amneal Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Amneal Pharmaceuticals, Inc. reported total board compensation of $3,883,822 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chirag Patel | $800,000 | $0 | $6,974,995 | $0 | $848,000 | $0 | $68,750 | $8,691,745 |
| Co-Chief Executive Officer and President | ||||||||
| Anastasios Konidaris | 600,750 | 0 | 2,249,995 | 0 | 423,590 | 0 | 19,159 | 3,293,494 |
| EVP & Chief Financial Officer | ||||||||
| Andrew Boyer | 613,846 | 0 | 1,912,500 | 0 | 471,658 | 0 | 19,159 | 3,017,163 |
| EVP, Chief Commercial Officer - Generics | ||||||||
| Jason Daly | 560,019 | 0 | 1,912,500 | 0 | 368,764 | 0 | 19,159 | 2,860,442 |
| EVP, Chief Legal Officer & Secretary | ||||||||
| Nikita Shah | 518,781 | 0 | 1,856,248 | 0 | 336,394 | 0 | 19,159 | 2,730,582 |
| EVP, Chief Human Resources Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Chirag Patel | $8,691,745 | $7,187,970 | — | ↑ +1,503,775 |
| Anastasios Konidaris | 3,293,494 | 2,852,333 | 1,891,266 | ↑ +441,161 |
| Andrew Boyer | 3,017,163 | 2,794,302 | 1,942,689 | ↑ +222,861 |
| Jason Daly | 2,860,442 | 2,383,794 | 1,349,396 | ↑ +476,648 |
| Nikita Shah | 2,730,582 | 2,373,664 | 1,533,232 | ↑ +356,918 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The primary objectives of our executive compensation program are to: attract, motivate and retain executive officers of outstanding ability and potential; reinforce the execution of our business strategy and the achievement of our business objectives; and align the interests of our executive officers with the interests of our stockholders, with the ultimate objective of increasing stockholder value.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Meridian |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Chirag Patel | PSU | 2025-03-03 | 222,603 | 445,205 | — | 890,410 | $4,874,995 |
| Jason Daly | PSU | 2025-03-03 | 48,516 | 97,032 | — | 194,064 | 1,062,500 |
| Nikita Shah | PSU | 2025-03-03 | 47,089 | 94,178 | — | 188,356 | 1,031,249 |
| Andrew Boyer | RSU | 2025-03-03 | — | — | 97,032 | — | 850,000 |
| Andrew Boyer | PSU | 2025-03-03 | 48,516 | 97,032 | — | 194,064 | 1,062,500 |
| Chirag Patel | RSU | 2025-03-03 | — | — | 239,276 | — | 2,100,000 |
| Chintu Patel | RSU | 2025-03-03 | — | — | 239,276 | — | 2,100,000 |
| Chintu Patel | PSU | 2025-03-03 | 222,603 | 445,205 | — | 890,410 | 4,874,995 |
| Anastasios Konidaris | RSU | 2025-03-03 | — | — | 114,155 | — | 999,998 |
| Anastasios Konidaris | PSU | 2025-03-03 | 57,078 | 114,155 | — | 228,310 | 1,249,997 |
| Jason Daly | RSU | 2025-03-03 | — | — | 97,032 | — | 850,000 |
| Nikita Shah | RSU | 2025-03-03 | — | — | 94,178 | — | 824,999 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Chirag Patel | $2,100,000 | $4,874,995 | $0 | 69.9% |
| Jason Daly | 850,000 | 1,062,500 | 0 | 55.6% |
| Nikita Shah | 824,999 | 1,031,249 | 0 | 55.6% |
| Andrew Boyer | 850,000 | 1,062,500 | 0 | 55.6% |
| Chintu Patel | 2,100,000 | 4,874,995 | 0 | 69.9% |
| Anastasios Konidaris | 999,998 | 1,249,997 | 0 | 55.6% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jason Daly | RSU | 22,645 | — | $285,327 |
| Nikita Shah | RSU | 36,232 | — | 456,253 |
| Andrew Boyer | RSU | 39,252 | — | 494,575 |
| Anastasios Konidaris | RSU | 45,290 | — | 570,654 |
| Jason Daly | RSU | 76,453 | — | 963,308 |
| Nikita Shah | RSU | 91,473 | — | 1,115,962 |
| Nikita Shah | RSU | 94,178 | — | 1,186,643 |
| Nikita Shah | PSU | 94,178 | — | 1,186,643 |
| Andrew Boyer | RSU | 97,032 | — | 1,222,603 |
| Andrew Boyer | PSU | 97,032 | — | 1,222,603 |
| Jason Daly | RSU | 97,032 | — | 1,222,603 |
| Jason Daly | PSU | 97,032 | — | 1,222,603 |
| Andrew Boyer | RSU | 99,389 | — | 1,252,301 |
| Nikita Shah | RSU | 107,640 | — | 1,356,264 |
| Jason Daly | RSU | 107,640 | — | 1,356,264 |
| Anastasios Konidaris | RSU | 114,155 | — | 1,438,353 |
| Anastasios Konidaris | PSU | 114,155 | — | 1,438,353 |
| Andrew Boyer | RSU | 114,584 | — | 1,443,758 |
| Anastasios Konidaris | RSU | 114,679 | — | 1,444,955 |
| Anastasios Konidaris | RSU | 131,945 | — | 1,662,507 |
| Patel | RSU | 239,726 | — | 3,020,548 |
| Patel | RSU | 277,778 | — | 3,500,003 |
| Nikita Shah | PSU | 287,038 | — | 3,616,679 |
| Jason Daly | PSU | 287,038 | — | 3,616,679 |
| Andrew Boyer | PSU | 305,556 | — | 3,850,006 |
| Jason Daly | PSU | 305,810 | — | 3,853,206 |
| Anastasios Konidaris | PSU | 351,852 | — | 4,433,335 |
| Nikita Shah | PSU | 366,972 | — | 4,623,847 |
| Andrew Boyer | PSU | 397,554 | — | 5,009,180 |
| Patel | PSU | 445,205 | — | 5,609,583 |
| Anastasios Konidaris | PSU | 458,719 | — | 5,779,822 |
| Patel | PSU | 733,944 | — | 9,247,694 |
| Patel | PSU | 1,333,334 | — | 16,800,008 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Emily Peterson AlvaNot independent · Departed during FY | $67,500 | $250,000 | $0 | $0 | $335,638 | $653,138 |
| Paul MeisterIndependent · Board Chair · Compensation · Nominating and Corporate Governance (Chair) · Conflicts | 122,625 | 350,003 | 0 | 0 | — | 472,628 |
| John KielyIndependent · Audit (Chair) · Nominating and Corporate Governance | 132,500 | 250,000 | 0 | 0 | 52,094 | 434,594 |
| Jeff GeorgeIndependent · Compensation · Conflicts | 127,500 | 250,000 | 0 | 0 | 36,412 | 413,912 |
| Ted NarkIndependent · Compensation (Chair) · Nominating and Corporate Governance | 102,500 | 250,000 | 0 | 0 | 48,525 | 401,025 |
| J. Kevin BuchiIndependent · Audit (Chair) · Conflicts | 143,333 | 250,000 | 0 | 0 | — | 393,333 |
| Shlomo YanaiIndependent · Audit · Compensation | 99,792 | 250,000 | 0 | 0 | 36,795 | 386,587 |
| Deb AutorIndependent · Audit · Conflicts | 115,000 | 250,000 | 0 | 0 | — | 365,000 |
| Gautam PatelIndependent · Nominating and Corporate Governance · Conflicts | 75,000 | 250,000 | 0 | 0 | 38,605 | 363,605 |
| Chirag PatelEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Chintu PatelEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $75,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | $3 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $985,750 |
| Equity awards (grant-date value) | $2,350,003 |
| All other compensation | $548,069 |
| Total cost of the board | $3,883,822 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Amneal Pharmaceuticals as a peer
Companies that benchmark against AMRX
2 companies name AMRX as a compensation peer
- Emergent BioSolutions Inc.EBSFY2025
- Supernus, Inc.INDVFY2025
Each company listed discloses AMRX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AMRX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ALKS Alkermes plcAMPH Amphastar Pharmaceuticals, Inc.PBH Prestige Consumer Healthcare Inc.EBS Emergent BioSolutions Inc.JAZZ Jazz Pharmaceuticals plcNBIX Neurocrine Biosciences, Inc.UTHR United Therapeutics CorporationANIP ANI Pharmaceuticals, Inc.VTRS Viatris Inc.PCRX Pacira BioSciences, Inc.SUPN Supernus Pharmaceuticals, Inc.PRGO Perrigo Company plc
Peer reciprocity
The companies Amneal Pharmaceuticals, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | $1,003,269 | $16,138,433 | $0 | $1,980,000 | $19,151,558 |
| 2 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 3 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 4 | Viatris Inc. | 2025 | Scott Smith | 1,448,654 | 10,150,013 | 0 | 2,973,660 | 15,273,331 |
| 5 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 6 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 7 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 8 | Perrigo Company plc | 2025 | Patrick Lockwood-Taylor | 1,223,333 | 6,990,564 | 0 | 687,250 | 9,042,603 |
| 9 | Amneal Pharmaceuticals, Inc. | 2025 | Chirag Patel | 800,000 | 6,974,995 | 0 | 848,000 | 8,691,745 |
| 10 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 11 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 12 | Prestige Consumer Healthcare Inc. | 2026 | Ronald Lombardi | 1,003,564 | 4,099,959 | 0 | 850,000 | 6,004,547 |
| 13 | Emergent BioSolutions Inc. | 2025 | Joseph Papa | 1,037,385 | 1,638,500 | 1,191,500 | 1,446,640 | 5,321,147 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. | 106% | PSU 65 · RSU 35 | No | Meridian |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Emergent BioSolutions Inc. | 107% | Options 50 · PSU 50 | No | WTW |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Neurocrine Biosciences, Inc. | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| Perrigo Company plc | 44.3% | PSU 70 · RSU 30 | Yes — Relative TSR (rTSR) | Frederic W. Cook & Company, Inc. |
| Prestige Consumer Healthcare Inc. | 68% | PSU 75 · RSU 25 | No | not disclosed |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
| Viatris Inc. | 136.72% | PSU 65 · RSU 35 | No | Meridian Compensation Partners, LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-06 | 269,089,785 | 2,577,481 | 57,507 | 99.05% | Passed |
| 2025 | 2025-05-06 | 258,800,579 | 1,255,182 | 265,740 | 99.52% | Passed |
| 2024 | 2024-05-02 | 254,365,134 | 1,199,935 | 139,222 | 99.53% | Passed |
| 2023 | 2023-05-09 | 227,413,821 | 3,098,184 | 680,576 | 98.66% | Passed |
| 2022 | 2022-05-09 | 236,202,110 | 1,193,006 | 270,959 | 99.5% | Passed |
| 2021 | 2021-05-05 | 233,858,559 | 881,197 | 175,040 | 99.62% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-06 | 99.05%a |
| 2025 | 2025-05-06 | 99.52%b |
| 2024 | 2024-05-02 | 99.53%c |
a. Approved under the standard stated in the filing — “Abstentions will not affect the outcome of the vote for Proposal No.”.
b. Approved under the standard stated in the filing — “Abstentions will not affect the outcome of the vote for Proposal Nos.”.
c. Approved under the standard stated in the filing — “Abstentions will not affect the outcome of the vote for Proposal No.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 679 : 1 |
|---|---|
| CEO total compensation | $8,730,545 |
| Median employee compensation | $12,853 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Gautam Patel | Director | 2026-05-06 | A | 19,824 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Shlomo Yanai | Director | 2026-05-06 | A | 19,824 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Meister | Director | 2026-05-06 | A | 30,837 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ted Nark | Director | 2026-05-06 | A | 19,824 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Kiely | Director | 2026-05-06 | A | 19,824 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deb Autor | Director | 2026-05-06 | A | 19,824 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| J. Kevin Buchi | Director | 2026-05-06 | A | 19,824 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeff George | Director | 2026-05-06 | A | 19,824 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shlomo Yanai | Director | 2026-05-07 | A | 34,819 | — | — | Common | Form 4 ↗ |
| Ted Nark | Director | 2026-05-07 | D | 34,819 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeff George | Director | 2026-05-07 | A | 34,819 | — | — | Common | Form 4 ↗ |
| Deb Autor | Director | 2026-05-07 | A | 34,819 | — | — | Common | Form 4 ↗ |
| Shlomo Yanai | Director | 2026-05-07 | D | 34,819 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Meister | Director | 2026-05-07 | D | 48,747 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Meister | Director | 2026-05-07 | A | 48,747 | — | — | Common | Form 4 ↗ |
| John Kiely | Director | 2026-05-07 | A | 34,819 | — | — | Common | Form 4 ↗ |
| Gautam Patel | Director | 2026-05-07 | D | 34,819 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gautam Patel | Director | 2026-05-07 | A | 34,819 | — | — | Common | Form 4 ↗ |
| Jeff George | Director | 2026-05-07 | D | 34,819 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deb Autor | Director | 2026-05-07 | D | 34,819 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| J. Kevin Buchi | Director | 2026-05-07 | D | 34,819 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| J. Kevin Buchi | Director | 2026-05-07 | A | 34,819 | — | — | Common | Form 4 ↗ |
| Ted Nark | Director | 2026-05-07 | A | 34,819 | — | — | Common | Form 4 ↗ |
| John Kiely | Director | 2026-05-07 | D | 34,819 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Deb Autor | Director | 2026-05-11 | D | 34,819 | 13 | 450,558 | Common | Form 4 ↗ |
| Gautam Patel | Director | 2026-08-10 | A | 283,632 | — | — | Common | Form 4 ↗ |
| Chintu Patel | Director | 2026-08-10 | A | 6,381,734 | — | — | Common | Form 4 ↗ |
| Tushar Bhikhubhai Patel | Greater-than-10% holder | 2026-08-10 | A | 12,763,469 | — | — | Common | Form 4 ↗ |
| Chirag K. Patel | Director | 2026-08-10 | A | 6,381,734 | — | — | Common | Form 4 ↗ |
| J. Kevin Buchi | Director | 2026-08-11 | D | 168,573 | 17 | 2,896,084 | Common | Form 4 ↗ |
| Jason Daly | EVP, Chief Legal Officer | 2026-08-11 | D | 6,613 | 18 | 117,050 | Common | Form 4 ↗ |
| Jason Daly | EVP, Chief Legal Officer | 2026-08-12 | D | 210,000 | 17 | 3,654,000 | Common | Form 4 ↗ |
| Nikita Shah | Executive Vice President | 2026-08-12 | D | 146,403 | 18 | 2,563,517 | Common | Form 4 ↗ |
| John Kiely | Director | 2026-08-13 | D | 50,000 | 18 | 882,000 | Common | Form 4 ↗ |
| John Kiely | Director | 2026-08-13 | D | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Boyer | Executive Vice President | 2026-08-21 | D | 152,426 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Boyer | Executive Vice President | 2026-09-01 | D | 80,000 | 0 | 0 | Common | Form 4 ↗ |
| J. Kevin Buchi | Director | 2026-09-11 | D | 20,445 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| J. Kevin Buchi | Director | 2026-09-11 | A | 20,445 | 14 | 295,430 | Common | Form 4 ↗ |
| J. Kevin Buchi | Director | 2026-09-17 | D | 20,445 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (89 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Chirag Patel. DEF 14A, filed 2026-03-25. Section “Summary Compensation Table” · page 42. As printed: 8,691,745. View filing ↗
- Section 01, Anastasios Konidaris. DEF 14A, filed 2026-03-25. Section “Summary Compensation Table” · page 42. As printed: 3,293,494. View filing ↗
- Section 01, Andrew Boyer. DEF 14A, filed 2026-03-25. Section “Summary Compensation Table” · page 42. As printed: 3,017,163. View filing ↗
- Section 01, Jason Daly. DEF 14A, filed 2026-03-25. Section “Summary Compensation Table” · page 42. As printed: 2,860,442. View filing ↗
- Section 01, Nikita Shah. DEF 14A, filed 2026-03-25. Section “Summary Compensation Table” · page 42. As printed: 2,730,582. View filing ↗
- Section 03, Chirag Patel PSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Jason Daly PSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Nikita Shah PSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Boyer RSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Boyer PSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Chirag Patel RSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Chintu Patel RSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Chintu Patel PSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Anastasios Konidaris RSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Anastasios Konidaris PSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Jason Daly RSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Nikita Shah RSU. DEF 14A, filed 2026-03-25. Section “Grants of Plan Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-25. Section “CEO Pay Ratio”. As printed: 679 : 1. View filing ↗
- Section 08, Emily Peterson Alva. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 653,138. View filing ↗
- Section 08, Paul Meister. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 472,628. View filing ↗
- Section 08, John Kiely. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 434,594. View filing ↗
- Section 08, Jeff George. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 413,912. View filing ↗
- Section 08, Ted Nark. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 401,025. View filing ↗
- Section 08, J. Kevin Buchi. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 393,333. View filing ↗
- Section 08, Shlomo Yanai. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 386,587. View filing ↗
- Section 08, Deb Autor. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 365,000. View filing ↗
- Section 08, Gautam Patel. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 363,605. View filing ↗
- Section 08, Chirag Patel. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Chintu Patel. DEF 14A, filed 2026-03-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Gautam Patel 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shlomo Yanai 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Meister 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ted Nark 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kiely 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deb Autor 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Kevin Buchi 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff George 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shlomo Yanai 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ted Nark 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff George 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deb Autor 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shlomo Yanai 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Meister 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Meister 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kiely 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gautam Patel 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gautam Patel 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeff George 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deb Autor 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Kevin Buchi 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Kevin Buchi 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ted Nark 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kiely 2026-05-07. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Deb Autor 2026-05-11. Form 4, filed 2026-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gautam Patel 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chintu Patel 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tushar Bhikhubhai Patel 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chirag K. Patel 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Kevin Buchi 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Daly 2026-08-11. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Daly 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nikita Shah 2026-08-12. Form 4, filed 2026-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kiely 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Kiely 2026-08-13. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Boyer 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Boyer 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Kevin Buchi 2026-09-11. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Kevin Buchi 2026-09-11. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, J. Kevin Buchi 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-07. Item 5.07 · say-on-pay result. As reported: 99.05% (votes for as printed: 269,089,785). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-08. Item 5.07 · say-on-pay result. As reported: 99.52% (votes for as printed: 258,800,579). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-07. Item 5.07 · say-on-pay result. As reported: 99.53% (votes for as printed: 254,365,134). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 985,750 + equity 2,350,003 + all other 548,069 = 3,883,822, summed across the director compensation table rows.
- Jazz Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. View filing ↗
- United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
- Supernus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. View filing ↗
- Viatris Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Viatris Inc.'s own proxy. As printed: 15,273,331. View filing ↗
- Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
- Pacira BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. View filing ↗
- ANI Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. View filing ↗
- Perrigo Company plc, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Perrigo Company plc's own proxy. As printed: 9,042,603. View filing ↗
- Amneal Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Amneal Pharmaceuticals, Inc.'s own proxy. As printed: 8,691,745. View filing ↗
- Amphastar Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. View filing ↗
- Alkermes plc, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. View filing ↗
- Prestige Consumer Healthcare Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in Prestige Consumer Healthcare Inc.'s own proxy. As printed: 6,004,547. View filing ↗
- Emergent BioSolutions Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Emergent BioSolutions Inc.'s own proxy. As printed: 5,321,147. View filing ↗
- Section 10a, Emergent BioSolutions Inc. reciprocity. DEF 14A. Emergent BioSolutions Inc. names Amneal Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗